Drug Profile

Fasoracetam - Synaptiq Therapeutics

Alternative Names: Fasoracetam monohydrate- Nobias Therapeutics; NB 001 - Nobias Therapeutics; SYN 001 - Synaptiq Therapeutics

Latest Information Update: 04 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nobias Therapeutics
Class Antiepileptic drugs; Neuroprotectants; Nootropics; Piperidines; Small molecules
Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - DiGeorge syndrome
New Molecular Entity Yes

Highest Development Phases

Phase II DiGeorge syndrome

Most Recent Events

04 Aug 2026 Fasoracetam receives Rare Pediatric Disease Designation for DiGeorge syndrome in USA
23 Jul 2026 Synaptiq Therapeutics acquires Fasoracetam from Nobias Therapeutics
23 Jul 2026 Synaptiq Therapeutics plans a phase IIb trial for DiGeorge syndrome

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com